Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Anavex2-73
2. Tetrahydro-n, N-dimethyl-2,2-diphenyl-3-furanmethanamine Hydrochloride
1. 195615-83-9
2. Avex-73
3. Thd-dp-fm
4. Ae-37
5. Ae37
6. Blarcamesine [usan]
7. Anavex-2-73
8. 9t210mmz3f
9. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanemethanamine
10. 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine
11. Blarcamesine (usan)
12. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine
13. 3-furanmethanamine, Tetrahydro-n,n-dimethyl-2,2-diphenyl-
14. 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine
15. (r)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine
16. Unii-9t210mmz3f
17. Anavex
18. Ae 37
19. Blarcamesine [inn]
20. An2/avex-73
21. Avex-73?
22. Schembl181634
23. Chembl4297224
24. Gtpl11586
25. Dtxsid60941344
26. Bcp23552
27. Ex-a3143
28. Bdbm50559171
29. Anavex-2-73 Free Base (blarcamesine)
30. Db05592
31. Sb17187
32. Ncgc00387227-01
33. Ac-35490
34. Hy-105296
35. Cs-0025655
36. D11383
37. D87137
38. Q25110485
39. Rac-1-((3r)-2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine
| Molecular Weight | 281.4 g/mol |
|---|---|
| Molecular Formula | C19H23NO |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 281.177964357 g/mol |
| Monoisotopic Mass | 281.177964357 g/mol |
| Topological Polar Surface Area | 12.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 298 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in breast cancer.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Blarcamesine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Blarcamesine, including repackagers and relabelers. The FDA regulates Blarcamesine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Blarcamesine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Blarcamesine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Blarcamesine supplier is an individual or a company that provides Blarcamesine active pharmaceutical ingredient (API) or Blarcamesine finished formulations upon request. The Blarcamesine suppliers may include Blarcamesine API manufacturers, exporters, distributors and traders.
click here to find a list of Blarcamesine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Blarcamesine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Blarcamesine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Blarcamesine GMP manufacturer or Blarcamesine GMP API supplier for your needs.
A Blarcamesine CoA (Certificate of Analysis) is a formal document that attests to Blarcamesine's compliance with Blarcamesine specifications and serves as a tool for batch-level quality control.
Blarcamesine CoA mostly includes findings from lab analyses of a specific batch. For each Blarcamesine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Blarcamesine may be tested according to a variety of international standards, such as European Pharmacopoeia (Blarcamesine EP), Blarcamesine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Blarcamesine USP).
LOOKING FOR A SUPPLIER?
